全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Endostatin-Encapsulated N-Succinyl-Chitosan Nanoparticles Inhabited the Growth of MCF-7 Cell

DOI: 10.4236/oalib.1102083, PP. 1-9

Subject Areas: Nanometer Materials, Biological Materials

Keywords: N-Succinyl-Chitosan, Nanoparticle, Endostatin

Full-Text   Cite this paper   Add to My Lib

Abstract

A simple method was developed to synthesize the N-succinyl-chitosan (NSC) successfully. NSC was characterized by FTIR, 1H NMR and element analysis. The NSC can form nanoparticles with TPP through electrostatic interaction. The morphology, particle size and zeta potential of the nanoparticle were investigated and showed a 100 - 200 nm in diameter with a positive potential 9.99 mv. The encapsulation efficiency of NSC-ES-NPs was 94.76 ± 0.05. The in vitro cell culture indicates that NSC has non-toxicity and cell-compatibility. NSC-ES-NPs show antitumor activity against MCF-7 cell. Our results demonstrate that NSC has great potential in the drug controlled release delivery.

Cite this paper

Fan, Y. , Li, Y. and Xia, X. (2015). Endostatin-Encapsulated N-Succinyl-Chitosan Nanoparticles Inhabited the Growth of MCF-7 Cell. Open Access Library Journal, 2, e2083. doi: http://dx.doi.org/10.4236/oalib.1102083.

References

[1]  Luo, H., Li, J. and Chen, X. (2010) Antitumor Effect of N-Succinyl-Chitosan Nanoparticles on K562 Cells. Biomedicine & Pharmacotherapy, 64, 521-526.
http://dx.doi.org/10.1016/j.biopha.2009.09.002
[2]  Park, J.H., Saravanakumar, G., Kim, K., et al. (2010) Targeted Delivery of Low Molecular Drugs Using Chitosan and Its Derivatives. Advanced Drug Delivery Reviews, 62, 28-41.
http://dx.doi.org/10.1016/j.addr.2009.10.003
[3]  Ying, G.Q., Yang, H., Yi, Y., et al. (2007) Relationships between the Molecular Structure and Moisture-Absorption and Moisture-Retention Abilities of Succinyl Chitosan. Polymer Bulletin, 59, 509-516.
http://dx.doi.org/10.1007/s00289-007-0790-9
[4]  Sui, W., Wang, Y., Dong, S, et al. (2008) Preparation and Properties of an Amphiphilic Derivative of Succinyl- Chito- san. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 316, 171-175.
http://dx.doi.org/10.1016/j.colsurfa.2007.09.016
[5]  Zhu, A.P., Chen, T., Yuan, L.H., Wu, H. and Lu, P. (2006) Synthesis and Characterization of N-Succinyl-Chitosan and Its Self-Assembly of Nanospheres. Carbohydrate Polymers, 66, 274-279.
http://dx.doi.org/10.1016/j.carbpol.2006.03.014
[6]  Kato, Y., Onishi, H. and Machida, Y. (2001) Biological Characteristics of Lactosaminated N-Succinyl-Chitosan as a Liver-Specific Drug Carrier in Mice. Journal of Controlled Release, 70, 295-307.
http://dx.doi.org/10.1016/S0168-3659(00)00356-4
[7]  Kato, Y., Onishi, H. and Machida, Y. (2001) Lactosaminated and Intact N-Succinyl-Chitosans as Drug Carriers in Liver Metastasis. International Journal of Pharmaceutics, 226, 93-106.
http://dx.doi.org/10.1016/S0378-5173(01)00777-3
[8]  Asai, K., Kanazawa, H., Otani, K., et al. (2002) Imbalance between Vascular Endothelial Growth Factor and Endostatin Levels in Induced Sputum from Asthmatic Subjects. Journal of Allergy and Clinical Immunology, 110, 571-575.
http://dx.doi.org/10.1067/mai.2002.127797
[9]  Qian, C.N., Zhang, C.Q., Guo, X., et al. (2000) Elevation of Serum Vascular Endothelial Growth Factor in Male Patients with Metastatic Nasopharyngeal Carcinoma. Cancer, 88, 255-261.
http://dx.doi.org/10.1002/(SICI)1097-0142(20000115)88:2
<255::AID-CNCR2>3.0.CO;2-N

[10]  Takeda, A., Shimada, H., Imaseki, H., et al. (2000) Clinical Significance of Serum Vascular Endothelial Growth Factor in Colorectal Cancer Patients: Correlation with Clinicopathological Factors and Tumor Markers. Oncology Reports, 7, 333-338.
http://dx.doi.org/10.3892/or.7.2.333
[11]  Jones A, Fujiyama C, Turner K, et al. (2000) Elevated Serum Vascular Endothelial Growth Factor in Patients with Hormone-Escaped Prostate Cancer. BJU International, 85, 276-280.
http://dx.doi.org/10.1046/j.1464-410x.2000.00432.x
[12]  Suzuki, M., Iizasa, T., Ko, E., et al. (2002) Serum Endostatin Correlates with Progression and Prognosis of Non-Small Cell Lung Cancer. Lung Cancer, 35, 29-34.
http://dx.doi.org/10.1016/S0169-5002(01)00285-9
[13]  Folkman, J. (2006) Antiangiogenesis in Cancer Therapy—Endostatin and Its Mechanisms of Action. Experimental Cell Research, 312, 594-607.
http://dx.doi.org/10.1016/j.yexcr.2005.11.015
[14]  O’Reilly, M.S., Boehm, T., Shing, Y., et al. (1997) Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell, 88, 277-285.
http://dx.doi.org/10.1016/S0092-8674(00)81848-6
[15]  Nilsson, U.W. and Dabrosin, C. (2006) Estradiol and Tamoxifen Regulate Endostatin Generation via Matrix Metalloproteinase Activity in Breast Cancer in Vivo. Cancer Research, 66, 4789-4794.
http://dx.doi.org/10.1158/0008-5472.CAN-05-4012
[16]  Abdollahi, A., Hahnfeldt, P., Maercker, C., et al. (2004) Endostatin’s Antiangiogenic Signaling Network. Molecular Cell, 13, 649-663.
http://dx.doi.org/10.1016/S1097-2765(04)00102-9
[17]  Hajitou, A., Grignet, C., Devy, L., et al. (2002) The Antitumoral Effect of Endostatin and Angiostatin Is Associated with a Down-Regulation of Vascular Endothelial Growth Factor Expression in Tumor Cells. The FASEB Journal, 16, 1802-1804.
http://dx.doi.org/10.1096/fj.02-0109fje

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413